Brexpiprazole Impurity 74
✓
100% accuracy
of data
24/7 scientific
support
⬡
0% tolerance in
quality of product

Stock Locations

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

Brexpiprazole Impurity 74

● In Stock

Catalogue No.:VE0025278
CAS No.:N/A
Mol. Formula:C26H27ClN2O4
Mol. Weight:466.96 g/mol

Additional information on Brexpiprazole Impurity 74

Parent drug

Brexpiprazole

IUPAC Name

7-(4-((2-(4-chlorobutoxy)quinolin-7-yl)oxy)butoxy)quinolin-2(1H)-one

Pharmacopoeial Synonyms

N/A

Other Synonyms

N/A

Smiles

O=C(C=C1)NC2=C1C=CC(OCCCCOC3=CC(N=C(OCCCCCl)C=C4)=C4C=C3)=C2

InChI

InChI=1S/C26H27ClN2O4/c27-13-1-2-16-33-26-12-8-20-6-10-22(18-24(20)29-26)32-15-4-3-14-31-21-9-5-19-7-11-25(30)28-23(19)17-21/h5-12, 17-18H, 1-4, 13-16H2, (H, 28, 30)

Description

Brexpiprazole Impurity 74 is a defined related substance observed during synthesis and stability studies of brexpiprazole. Robust analytical characterization using HPLC with UV detection, LC-MS and NMR is recommended to establish retention time, molecular weight and structural assignment. The impurity may arise from incomplete reactions or oxidative degradation and should be included in the impurity profile and control strategy according to ICH Q3A and Q3B guidelines. Establish qualification thresholds, validated quantification methods and appropriate purification steps to minimize levels. Stability-indicating methods, forced degradation studies and routine batch release testing ensure regulatory compliance and product quality.

Request a Quote

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Products quotation
Name
Url